Showing results (141-150 of 399) with videos related to

Sort By:
Pageof 40
Annals of Hematology|January 4, 2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromesAmer M Zeidan, Daniel J DeAngelo, Jeanne Palmer, et al.
The Lancet. Haematology|December 5, 2024
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Gail J Roboz, Renato Bassan, et al.
Haematologica|April 23, 2026
Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancersClark DuMontier, Angel M Cronin, Tammy T Hshieh, et al.
Experimental Hematology|February 26, 2005
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemiaW Nicholas Haining, Angelo A Cardoso, Heather L Keczkemethy, et al.
Leukemia Research|September 9, 2006
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) projectJune M McKoy, Cara Angelotta, Charles L Bennett, et al.
Leukemia|January 4, 2024
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium ProtocolsYannis K Valtis, Yael Flamand, Shai Shimony, et al.
Blood|June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Cancer Research|October 31, 2019
Phosphorylation of RAB7 by TBK1/IKKε Regulates Innate Immune Signaling in Triple-Negative Breast CancerJessica L Ritter, Zehua Zhu, Tran C Thai, et al.
Pageof 40